SARS-CoV-2 spike therapeutic antibodies in the age of variants

Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Baum, Alina, Kyratsous, Christos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Found in Translation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056769/
https://www.ncbi.nlm.nih.gov/pubmed/33871567
http://dx.doi.org/10.1084/jem.20210198
Descripción
Sumario:Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2.

Ejemplares similares